New hope for bladder cancer patients: experimental drug combo aims to beat chemo

NCT ID NCT07424287

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This Phase 3 trial is testing whether a combination of an experimental drug (SHR-1501) plus the standard immunotherapy BCG works better than chemotherapy for people with a type of bladder cancer (papillary-only NMIBC) that no longer responds to BCG alone. The study plans to enroll 236 adults who have had all visible tumors removed. The main goal is to see how long the cancer stays away. The trial is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1501 (an experimental drug) combined with BCG (a standard immunotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with bladder cancer that no longer responds to BCG alone, potentially delaying or avoiding the need for bladder removal.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The experimental combination may not be more effective than chemotherapy, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCG-UNRESPONSIVE PAPILLARY-ONLY NON-MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder papillary urothelial carcinoma non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NMIBC

Contacts and locations

Locations

Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China
Renji Hospital Affiliated to Shanghai Jiao Tong University School
RECRUITING

Shanghai, Shanghai Municipality, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.